CANY
IRWD icon

Caxton Associates (New York)’s Ironwood Pharmaceuticals IRWD Stock Holding History

Caxton Associates (New York)’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-85,578
Closed -$911K – 513
2023
Q2 		$911K Buy
+85,578
New +$920K 0.13% 163
2020
Q1 		– Sell
-55,944
Closed -$745K – 490
2019
Q4 		$745K Buy
+55,944
New +$617K 0.1% 117

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Caxton Associates (New York)'s IRWD Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2023, closing a stake of 85,578 shares — an estimated $911K sold.

Caxton Associates (New York) first reported a position in IRWD in Q4 2019 and held it in 2 quarters. The position peaked at $911K in Q2 2023. 248 funds tracked by Wall St. Rank hold IRWD as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Ironwood Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 85,578 Ironwood Pharmaceuticals shares in Q3 2023, an estimated $911K.
  • Caxton Associates (New York) first reported a position in Ironwood Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Caxton Associates (New York)'s Ironwood Pharmaceuticals position peaked at $911K in Q2 2023.
  • 248 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.